SystImmune, Inc. Set to Showcase Breakthrough Global Data for Iza-bren (izalontamab brengitecan) in Lung Cancer at WCLC Congress 2026

- New global Phase 1 data from a randomized dose-expansion cohort of iza-bren in previously treated EGFR-mutated metastatic NSCLC demonstrate promising antitumor activity and a tolerable safety profile, supporting selection of 2.5 mg/kg D1D8 Q3W as the recommended Phase 3…